15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Assembly Biosciences Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $38.00 to $50.00, so the covering firms are broadly aligned. The average target of $44.00 sits 72% above the current $25.51. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -56% this year and 2% next, consensus EPS building from about $-0.51 next quarter toward $-2.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Assembly Biosciences Inc.
As of Jul, 4 of 4 firms rate ASMB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ASMB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.51
Range $-0.69 – $-0.32 · 2 analysts · -30% YoY
Next period, 2 analysts expect Assembly Biosciences Inc to earn $-0.51 a share (range $-0.69 – $-0.32), versus $-0.72 a year earlier. Full-year consensus is $0.14, growing to $-2.10 the year after.
REVENUE · NEXT QUARTER
$6.2M
Range $0 – $10.6M · 2 analysts · -23% YoY
Revenue is expected to reach $6.2M (range $0 – $10.6M), -23.0% year-over-year. Full-year consensus is $45.5M, rising to $32.3M next year.
Top analysts covering Assembly Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ASMB.
#1
Ed Arce
HC Wainwright & Co. · Rank #107
Hold
No targeton ASMB
Overall win rate
44%
+ Follow
#2
Roy Buchanan
JMP Securities · Rank #109
Buy
$38.00+49.0% to target
Overall win rate
48%
+ Follow
#3
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$50.00+96.0% to target
Overall win rate
35%
+ Follow
#4
Vamil Divan
Guggenheim
Buy
$43.00+68.6% to target
Coverage
—
+ Follow
#5
Salim Syed
Mizuho
Buy
$45.00+76.4% to target
Coverage
—
+ Follow
ASMB stock forecast FAQ
What is ASMB's average 12-month price target?+
The 4 analysts with a live target average $44.00 for Assembly Biosciences Inc over the next 12 months, ranging from a $50.00 high to a $38.00 low.
Is ASMB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ASMB?+
The Street-high target is $50.00 (HC Wainwright & Co.), and the Street-low is $38.00 (JMP Securities). The average of all 4 active targets is $44.00.
How many Wall Street analysts cover ASMB?+
4 analysts have an active rating on Assembly Biosciences Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ASMB?+
Among analysts who currently cover ASMB, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #107). Their current call is Hold.
What is Assembly Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.51 per share (range $-0.69 – $-0.32) across 2 analysts. Full-year EPS is projected at $0.14, rising to $-2.10 the following year.
How much revenue is Assembly Biosciences Inc expected to report next quarter?+
Consensus revenue is $6.2M (range $0 – $10.6M). Full-year revenue is projected at $45.5M, growing to $32.3M next year.
Have analysts been upgrading or downgrading ASMB lately?+
As of Jul, 4 of 4 firms rate ASMB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ASMB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
